OncoTargets and therapy最新文献

{"title":"Advances in the Treatment of Breast Cancer at Different Stages of Pregnancy.","authors":"Jiajin Lv, Xu Lin","doi":"10.2147/OTT.S586690","DOIUrl":"https://doi.org/10.2147/OTT.S586690","url":null,"abstract":"<p><p>Pregnancy-associated breast cancer (PABC) refers to newly occurring breast cancer from the beginning of pregnancy to within one year after delivery. In recent years, with changes in societal attitudes toward fertility, the number of women marrying and giving birth at older ages has steadily increased. The delay in the age of childbearing has gradually increased the risk of women being exposed to breast cancer during pregnancy, and thus the incidence of PABC has been on the rise. The treatment of PABC is challenging. The treatment plan should not only control the tumor progression of the patient but also ensure the healthy development of the fetus. Therefore, it is very important to formulate an individualized diagnosis and treatment plan. Thus, this article explores the diagnosis and treatment methods of PABC to respectively expound the feasibility and safety of the relevant diagnosis and treatment means in the first, second and third trimesters of pregnancy.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"19 ","pages":"586690"},"PeriodicalIF":2.8,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Genomics in the Development and Treatment of Multiple Myeloma: Understanding the Challenges and Opportunities.","authors":"Lu Ren, Feige Ru, Kun Zhang","doi":"10.2147/OTT.S595435","DOIUrl":"https://doi.org/10.2147/OTT.S595435","url":null,"abstract":"<p><p>This review aims to provide a comprehensive overview of recent advances in the genomics of multiple myeloma and their clinical implications. Multiple myeloma is a hematologic malignancy originating from bone marrow plasma cells, characterized by the infiltration of pathological plasma cells, osteolytic bone lesions, and the presence of monoclonal immunoglobulins in serum and/or urine. Multiple myeloma exhibits significant genetic heterogeneity, which is the core reason for the considerable variability in patient prognosis, differential treatment responses, and the eventual development of drug resistance. In recent years, with the rapid development of high-throughput sequencing technologies (such as next-generation sequencing, single-cell sequencing) and bioinformatics, our understanding of genomic abnormalities in multiple myeloma has reached an unprecedented depth. Importantly, these genomic abnormalities have begun to directly inform clinical practice, holding significant promise particularly in risk stratification, treatment selection, minimal residual disease monitoring, and early warning of relapse. This review systematically outlines the latest research progress in the field of multiple myeloma genomics. It focuses on elucidating the function and clinical significance of key driver gene mutations (eg, NRAS/KRAS, TP53, MYC), delves into the roles of copy number variations (particularly 1q21 amplification), epigenetic dysregulation (including DNA methylation, histone modifications), and non-coding RNAs in multiple myeloma pathogenesis. Furthermore, this review looks forward to future developments, including targeted and immunotherapeutic strategies guided by genomics, as well as the use of liquid biopsy for minimal residual disease monitoring, offering new insights into the precision diagnosis and treatment of multiple myeloma.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"19 ","pages":"595435"},"PeriodicalIF":2.8,"publicationDate":"2026-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13101822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the Correlation Between Hypoalbuminemia and Adverse Effects of Oral Anticancer Medications in Adult Patients with Solid Tumors: A Single-Center Retrospective Cohort Study in Saudi Arabia.","authors":"Nada Alsuhebany, Yara Alsaeed, Rema Ahmad Aldugiem, Sarah Alwaily, Wesam Abdel-Razaq, Sahar Alghamdi, Abdulaale R Almutairi, Salwa Y Hafez, Nadin Almosnid, Tariq Alqahtani","doi":"10.2147/OTT.S554707","DOIUrl":"https://doi.org/10.2147/OTT.S554707","url":null,"abstract":"<p><strong>Background: </strong>Hypoalbuminemia is commonly seen in cancer patients. Albumin is essential in drug binding and distribution, particularly in medications with a binding affinity of ≥95% such as tyrosine kinase inhibitors (TKIs). However, hypoalbuminemia can cause an increase in free drug concentration of highly protein-bound drugs, which can enhance drug exposure and cause adverse events. Hypoalbuminemia can significantly affect pharmacokinetics, increasing free drug concentrations and unbound drug in plasma as a consequence of low albumin levels. These alterations in pharmacokinetics can affect patients' tolerability to medications. The study aims to elucidate the impact of albumin levels on medication tolerability and the incidence of adverse events in adult patients with solid tumors.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted of all adult patients with solid tumors receiving tyrosine kinase inhibitors (TKIs) with ≥95% protein binding at the Ministry of National Guards Health Affairs-affiliated hospitals, Riyadh, Saudi Arabia. Electronic medical records were reviewed to identify eligible patients initiated on TKIs between January 1, 2016 and December 31, 2022. The main outcomes of this study were survival proportions, grading adverse events, and treatment failure rates in relation to albumin levels.</p><p><strong>Results: </strong>The study included 127 patients out of 450 patients receiving 19 oral TKIs and were divided into two groups (Group A: 51.2% with hypoalbuminemia, and Group B: 48.8% without hypoalbuminemia). Results reveal a significant correlation between hypoalbuminemia and decreased survival proportions by 22% (p-value= 0.04). Additionally, the study identifies a pattern in severity of adverse events, with grade 1 being the most common. Treatment failure is observed more frequently in patients with hypoalbuminemia compared to those with normal albumin levels.</p><p><strong>Conclusion: </strong>This study conducted among a Saudi population demonstrates the critical role of serum albumin levels in predicting TKIs tolerability and treatment success in patients with solid tumors. Assessing and addressing nutritional status and serum albumin before and during TKI treatment may help clinicians identify high‑risk patients and optimize supportive care. Larger prospective studies in diverse populations are needed to validate these findings.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"19 ","pages":"554707"},"PeriodicalIF":2.8,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracellular Vesicles in Pancreatic Cancer Function and Potential Clinical Applications.","authors":"Dai Li, Jian-Jun Fang, Zhi-Long Jiang","doi":"10.2147/OTT.S591622","DOIUrl":"https://doi.org/10.2147/OTT.S591622","url":null,"abstract":"<p><p>Pancreatic cancer (PC) is one of the most aggressive gastrointestinal malignancies, characterized by a dismal 5-year survival rate. This poor prognosis is primarily attributed to delayed early detection, rapid disease progression, surgical complexities, and the limited efficacy of conventional oncological therapies. Extracellular vesicles (EVs) are nanoscale, cell-secreted vesicles that transport bioactive cargoes, including nucleic acids, proteins, and lipids. Upon release into the extracellular space, EVs facilitate short and long-distance intercellular communication and molecular transport via multiple pathways. In this review, we elucidate the multifaceted roles of EVs within the highly malignant PC microenvironment, specifically focusing on their mediation of intricate crosstalk between tumor and stromal cells. Furthermore, we summarize potential EV-based biomarkers for PC diagnosis and the recent advances in leveraging EVs as therapeutic platforms across radiotherapy, gene therapy, and immunotherapy. Ultimately, this review aims to provide novel insights into the clinical management of PC to improve patient outcomes and quality of life.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"19 ","pages":"591622"},"PeriodicalIF":2.8,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13071294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147691379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>let-7d</i> Suppresses Proliferation and Invasion and Promotes Apoptosis of Meningioma by Targeting AEG-1 [Retraction].","authors":"","doi":"10.2147/OTT.S614704","DOIUrl":"https://doi.org/10.2147/OTT.S614704","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.2147/OTT.S141008.].</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"19 ","pages":"614704"},"PeriodicalIF":2.8,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13070399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147675703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma: A Single-Center Case Series of Five Patients.","authors":"XiaoYu Sun, Yanze Liu, Jie Peng, Jiaqi Liu","doi":"10.2147/OTT.S595202","DOIUrl":"https://doi.org/10.2147/OTT.S595202","url":null,"abstract":"<p><strong>Background: </strong>Diffuse sclerosing variant papillary thyroid carcinoma (DSVPTC) is a rare subtype of papillary thyroid carcinoma characterized by diffuse intrathyroidal involvement and frequent cervical lymph node metastasis. This study aims to delineate the clinicopathologic features, treatment outcomes, and recurrence patterns of DSVPTC.</p><p><strong>Methods: </strong>We retrospectively reviewed five patients with histopathologically confirmed DSVPTC treated at Zibo Central Hospital between 2009 and 2025. Follow-up data were collected until December 30, 2025.</p><p><strong>Results: </strong>Patients were aged 22-54 years (median: 41 years) and 60% (3/5) were female. Hashimoto's thyroiditis was present in 80% (4/5). All patients presented with diffuse microcalcifications on ultrasound (100%, 5/5). Thyroid FNA was performed in 80% (4/5) and all aspirates were Bethesda category VI. Cervical lymph node metastasis was observed in all patients: central compartment in 100% (5/5) and lateral neck in 60% (3/5). TNM staging (8th edition) included: pT1aN1aM0 (n=1), pT1aN1bM0 (n=1), pT3bN1aM0 (n=1), pT3bN1bM0 (n=2). According to ATA risk stratification, 3 patients were classified as high risk and 2 as intermediate risk. All patients underwent total thyroidectomy with bilateral central neck dissection. Lateral neck dissection was performed in 3 patients with radiologic evidence of lateral nodal disease. All patients received TSH suppression therapy (TSH <0.1 mIU/L) and two courses of I-131 therapy (100 mCi per course) at 3 and 6 months postoperatively. With a median follow-up of 2 years (range: 1-16 years), structural recurrence occurred in 2 patients (40%, 2/5) in the ipsilateral lateral neck at 1 and 4 years, respectively. No distant metastasis or disease-specific death occurred.</p><p><strong>Conclusion: </strong>In this small series of five patients, DSVPTC commonly presented as a nodule-negative \"snowstorm\" microcalcification phenotype with high nodal burden. Despite aggressive multimodal therapy including total thyroidectomy, TSH suppression, and scheduled radioiodine, lateral neck recurrence occurred in 40% of patients. Meticulous preoperative lateral neck assessment and long-term imaging-based surveillance remain essential.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"19 ","pages":"595202"},"PeriodicalIF":2.8,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13069954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147675754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of an m7G-Related lncRNA Signature for Prognostic Prediction and Immune Landscape Characterization in Early Gastric Cancer.","authors":"Yuan Zhang, Hongmei Cai, Kaige Yin, Li Liu, Mingshuang Yang, Chenguang Ji","doi":"10.2147/OTT.S582487","DOIUrl":"https://doi.org/10.2147/OTT.S582487","url":null,"abstract":"<p><strong>Background: </strong>While early gastric cancer (EGC) is generally associated with a favorable prognosis, its clinical outcomes are notably heterogeneous. Unlike advanced gastric cancer requiring uniform intensive treatment, EGC lacks robust biomarkers to identify high-risk patients for personalized therapy. Although both N7-methylguanosine (m7G) modification and long non-coding RNAs (lncRNAs) are involved in tumorigenesis, the prognostic value of m7G-related lncRNAs in EGC remains poorly defined.</p><p><strong>Methods: </strong>Based on TCGA-EGC data, we identified m7G-related lncRNAs with prognostic significance and constructed a prognostic model for m7G-related lncRNAs using univariate Cox and LASSO. The expression of the model genes was further validated by qRT-PCR. A series of statistical and bioinformatic analyses, including survival analysis, ROC curves, multivariate Cox regression, GSEA, immune infiltration, tumor mutation burden (TMB), and drug sensitivity assays, were performed to evaluate the prognostic performance and underlying biological characteristics of the signature.</p><p><strong>Results: </strong>A six-m7G-related-lncRNA risk model effectively stratified EGC patients into high- and low-risk groups with significantly distinct overall survival. The risk score was confirmed as an independent prognostic factor by univariate and multivariate Cox analysis. Pathway differences between risk groups were primarily enriched in tumor microenvironment regulation terms. Notably, the high-risk group exhibited an immunosuppressive tumor microenvironment correlated with immune escape. TMB analysis showed a negative correlation between the risk score and TMB, with the high-risk and low-TMB subgroup exhibiting the poorest prognosis. In silico drug sensitivity analysis further suggested that high-risk patients may develop poorer sensitivity to five clinical drugs, including Cisplatin, Oxaliplatin, and Vinorelbine.</p><p><strong>Conclusion: </strong>The six-m7G-related-lncRNA signature represents a promising prognostic tool for EGC that may facilitate personalized risk stratification and guide clinical decision-making regarding adjuvant or immunotherapeutic strategies.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"19 ","pages":"582487"},"PeriodicalIF":2.8,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13071161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147691375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Doxorubicin and Edelfosine Combo-Loaded Lipid-Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma [Retraction].","authors":"","doi":"10.2147/OTT.S614697","DOIUrl":"https://doi.org/10.2147/OTT.S614697","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.2147/OTT.S259428.].</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"19 ","pages":"614697"},"PeriodicalIF":2.8,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13070123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147675679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>miR-218</i> Overexpression Suppresses Tumorigenesis of Papillary Thyroid Cancer via Inactivation of PTEN /PI3K/AKT Pathway by Targeting Runx2 [Retraction].","authors":"","doi":"10.2147/OTT.S614707","DOIUrl":"https://doi.org/10.2147/OTT.S614707","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.2147/OTT.S172152.].</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"19 ","pages":"614707"},"PeriodicalIF":2.8,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13070121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147675729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Downregulation of Long Noncoding RNA TUG1 Inhibits Proliferation and Induces Apoptosis Through the TUG1/miR-142/ZEB2 Axis in Bladder Cancer Cells [Retraction].","authors":"","doi":"10.2147/OTT.S614701","DOIUrl":"https://doi.org/10.2147/OTT.S614701","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.2147/OTT.S124595.].</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"19 ","pages":"614701"},"PeriodicalIF":2.8,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13070125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147675689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}